A study focused on the use of magic mushrooms in Canada found that nearly 80% of participants believed in the therapeutic potential of psilocybin for distressed patients. Furthermore, about two-thirds of the Canadian respondents agreed with the idea of making psilocybin legally available for those who need it.
Besides advocating for wider access to the substance, a considerable 84.8 percent of participants felt that the public health system should bear the expense of such treatments. A majority of Canadians see psilocybin as a feasible treatment, especially for addressing end-of-life distress.
[toc]
Key Findings:
- People from Québec, Ontario, Alberta, and British Columbia believe in the medicinal potential of psilocybin for dealing with end-of-life existential distress.
- Magic mushrooms are seen as a safe option for treating existential distress.
- Participants in two double-blind studies experienced immediate and long-lasting benefits, with effects persisting for six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. It may manifest as feelings of helplessness, isolation, anxiety, and loss of purpose. This kind of distress is particularly prevalent among patients with life-threatening illnesses and can lead to thoughts of hastening death or suicide.
Usually, those facing terminal illnesses or major life changes are most susceptible to this type of distress. It significantly impacts their mental health and overall quality of life.
Existential therapy aims to manage issues like anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. While it can be helpful, it often requires multiple sessions and might not work for everyone.
The uncertainty about the effectiveness of such therapy is a major reason why many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Method
Over the last two decades, preliminary clinical trials have highlighted the potential benefits of psychedelic substances in addressing complex mental health conditions. Specifically, Psilocybin has been demonstrated to provide swift and sustained relief from existential distress in patients nearing the end of their lives.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are inadequate, Health Canada revised the Special Access Program in 2022. This revision enables healthcare providers to request controlled substances for their patients.
Canadian Support for Psilocybin Access
A research paper published in the Palliative Care Journal evaluates societal attitudes towards psilocybin-assisted therapy for end-of-life care. The data from this study include:
| Methodology | Input from 2,800 Canadians across Québec, Ontario, Alberta, and British Columbia. Among these, 19% had previous experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a legitimate medical option for addressing end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% support the public health system providing this therapy. 44.2% believe healthcare professionals should be allowed to administer the substance without Health Canada’s oversight. |
The findings align with survey data from Canada, England, and Australia. The researchers underscore that their study stands apart as it focuses on the use of psychoactive substances to manage existential distress in end-of-life situations.
Why Canadians Support Psilocybin Use
An increasing number of Canadians are endorsing the use of psilocybin for treatment, largely due to evidence from esteemed research institutions. Another factor is the perceived safety of psilocybin mushrooms in mitigating existential distress. Participants across multiple studies have not reported severe adverse health effects, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and enduring The benefits of the therapy can last up to six months or more. The effectiveness of the therapy is primarily due to mystical experiences that elicit feelings of unity and deep emotional insights. |
| Trial at New York University | 29 patients were randomly chosen to receive either psilocybin or the active placebo niacin. | The results were consistent with the Johns Hopkins study. Participants who received psilocybin reported psychological relief and a renewed perspective on life and death. |
| BMC Palliative Care | The study interviewed nineteen participants, including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist. The aim was to understand how professionals in palliative care perceive existential distress and their views on psychedelic therapy as a treatment option. | Palliative care practitioners believe that psychedelic-assisted therapy (PAT) has the potential to alleviate existential distress. |
Patient Experiences
In addition to scientific studies, numerous patient narratives also support the effectiveness of psilocybin in improving mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, who was diagnosed with terminal stage 4 pancreatic cancer, shares a transformative experience during her assisted therapy. In her vision, she is on a raft, surrounded by nature, and accompanied by mystical creatures. This vision brings her a profound sense of the universe’s interconnectedness and support, providing her with immense peace and affirmation.
Despite availing traditional mental health services, Yokoi continued to struggle with severe anxiety and distress after her diagnosis. Psilocybin therapy helped her to reconnect with her body and provided a tangible sense of love and support, significantly improving her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare at the time of the study and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy reported significant reductions in her anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs since her therapy session, she stated that the experiences had given her beliefs more substance and reality.
Brenda’s Journey
Throughout her therapy, Brenda experienced the sensation of death on two occasions. She came out of these experiences without fear of death, perceiving it as a beautiful part of the cycle of life. She credited the study as the catalyst for her healing process from childhood trauma. The data collected confirmed this dramatic change.
Key improvements included decreased anxiety and fear of death, coupled with an increased sense of spirituality.
Availability of Magic Mushroom Products in Canada
At present, the supply of psilocybin capsules and other products designed to manage existential distress or other mental health conditions may be limited. However, reliable online dispensaries can be a valuable resource for obtaining these products when needed.
| Characteristic | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some neighboring South American countries. | Discovered in Cambodia, around the Angkor Wat Temple. | Related to the Penis Envy mushrooms, which became prominent in the 1970s. |
| Potency | Moderate potency; suitable for beginners. | Moderate potency as well; perfect for those starting out. | High potency; advised for users with intermediate to advanced experience. |
| Effects | Causes a mental buzz, mild disorientation, enhanced color perception, euphoria, spiritual encounters, increased creativity, and improved focus. | Triggers an energizing and lasting high, slight visual changes, increased creativity, euphoria, a gentle physical high, fractal images, and feelings of joy. | Generates profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, focus, social awareness, and mood enhancement. |
Mitigate End-of-life Discomfort with Psilocybin Products
Existential or end-of-life distress can significantly burden many patients as they near the end of their lives. Conventional treatments for this distress can often be inadequate, contributing to a surge in Canadian support for easier access to magic mushrooms within public healthcare. This growing public interest could
We urge regulatory authorities to examine the potential of magic mushrooms as a valid treatment option. Acquire your psychedelics and mushroom delivery from Mushroom Gummies Canada.
Frequently Asked Questions
What can patients expect during Psilocybin-Assisted Therapy?
Experiences in Psychedelic-assisted therapy (PAT) can significantly differ among patients, making meticulous preparation and strict adherence to procedures crucial for positive results. Comprehensive screening and mental readiness are prerequisites before ingesting the substance.
- Pre-Session Preparation: Patients undergo an exhaustive assessment. The therapist reviews the patient’s goals and expectations to set clear intentions for the session. They also provide an overview of what to expect during the process.
- The Session: A controlled dose of the substance is administered to the patients in a serene, distraction-free environment to promote relaxation and self-reflection. The therapist remains present for continuous support and direction.
- Post-Session Integration Therapy: This therapy helps patients comprehend and interpret their experiences. Follow-up sessions provide ongoing support and counselling to reinforce the insights and changes gained during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, predominantly the 5-HT2A receptor. This interaction can induce alterations in perception, mood, and cognition, leading to profound shifts in consciousness, emotional disclosures, and fresh viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t appropriate for everyone. Patients suffering from particular mental health conditions or existential distress are thoroughly screened to exclude those with a past history of psychosis.
Related Articles:
